R079 (compound 17), a selective and orally active Nrf2 activator, enhances Nrf2 translocation activity (EC 50 = 32.41 μM) and can neutralize excess levels of reactive oxygen species by activating Nrf2. Additionally, R079 possesses anti-inflammatory properties and has applications in multiple sclerosis research [1].

Administered orally twice daily at doses of 30, 60, and 90 mg/kg for 28 days, the chemical compound R079 significantly reduced the severity of disease in a mouse model of experimental autoimmune encephalomyelitis (EAE), demonstrating a dose-dependent effect with an 89% reduction at the 60 mg/kg dosage [1]. Additionally, at doses of 60 and 90 mg/kg, R079 increased Nrf2 levels in the mouse thymus for up to 8 hours. Pharmacokinetic studies revealed that in Balb/c mice, R079 has a clearance rate of 2.01 mL/min/kg, a half-life of 1.0 hour, a steady-state volume of distribution of 0.14 L/kg, an oral AUC of 22900 ng·h/mL, an oral C max of 19600 ng/mL (73.96 μM), and a bioavailability of 56% [1].